Satake K, Takeuchi T
First Department of Surgery, Osaka City University Medical School, Japan.
Pancreas. 1994 Nov;9(6):720-4. doi: 10.1097/00006676-199411000-00008.
The carbohydrate antigen 19-9 (CA19-9) and radioimmunoassay have been shown to offer new hope for improving the diagnosis of pancreatic cancer, and various tumor markers (including SPan-1, DUPAN-2, and CA50) have been established. While clinical studies of these markers have found satisfactory sensitivities, only a few studies have compared these tumor markers on the same blood samples. We therefore evaluated the clinical efficacy of SPan-1, CA19-9, DUPAN-2, CA50, carcino-embryonic antigen, and Elastase 1 in detecting pancreatic cancer in identical blood samples.
碳水化合物抗原19-9（CA19-9）和放射免疫测定已被证明为改善胰腺癌诊断带来了新希望，并且已经建立了各种肿瘤标志物（包括SPAN-1、DUPAN-2和CA50）。虽然对这些标志物的临床研究发现了令人满意的敏感性，但只有少数研究在相同血样上比较了这些肿瘤标志物。因此，我们评估了SPAN-1、CA19-9、DUPAN-2、CA50、癌胚抗原和弹性蛋白酶1在检测相同血样中胰腺癌方面的临床疗效。
